Leading up to the Brisbane event on Tuesday.
Please review the minutes from the Sydney & Melbourne meetings and post here below some questions of a similar nature and content or clarification perhaps of those discussed in Melbourne & Sydney and please no tangential topics!
Thanks so much @rusty02
Sydney Minutes Of Meeting
More news flow in the coming weeks
Robert Clarke; Instimental in his DD on the company and an intregal part of fast tracking regletory and FDA obligations
Overseeing and working towards T/O and acquisitions but with an overall bussiness plan aiming at commercialisation and marketing.
28 assets developed in house
All with a distinct focus on reglatory obligations, commercialisation and marketing our assets
Hiring Heat of Corporate Development officer to oversee and concentrate on quick commercialisation of each assets
IHL42X
Approval from FDA massive acheivement in this short time via RC expertise.
47 sites 400-600 patients
Accessable market of $10bn
Trials to start in November once final reglatory obligations met
52 week trial with interum updates to the market at 3, 6 and 12 months
Restmed showing interest and IHL42X could be acquired before product design and marketing but still focused on the bussiness model to bring all assets to the market.
Restmed efficency on CPAP 46% IHL42X just under 60% 25% patients at 82% and 1 at 90%
No linguring side effects
PSI GAD
All applications nearing completion
Commited to manufacture and product design
FDA 4th qtr
IHL675A
Current phase 2 120 patients
Updates and interums 4 qtr
Gum
CanQuite N 5.2bn market
CanQuite O 64bn market
Rennecan Dermatology Massive market
6 EDA/EMA underway
Pre IND by xmas
Product design underway
Clinics
Many patient enquiries
Clinic ready in coming days and aiming at patient intake next month
Multi Bn market in Australia alone
World eyes are watching this space.
World leaders with Dr PL at the helm and highly regarded via Monarch
Cashflow positive very quickly with further clinics to open swiftly
Redomicile
Maximise assets in the US
Liquidity tight under current platform for larger US investors to take positions
Better CR opportunities due to more depth in liquidity
Easier for T/O or acquisitions
Mother company Delware to safeguard any hostile T/O or Acquisitions.
US share registry have been commissioned for the transition
Australian investorrs will be notified once redomiciled/transfer and a start up trading platform can be opened for trading direct through the US registry or choose their own broker.
Joel is activily finalising for SMSF to transfer into US entity
Hugh CR platform for Joel in the coming months with US interest.
R and D to stay in Australia. Government funded R and D programs to 47% expenditure.
Voting to be held some time in late October with swift Transfer within a week after shareholder approval
Aiming at early Novermber Transfer after a 2 week Traded Hault for US NASDAQ commission and to give shareholders time to set up their trading plateforms.
Joel and team were awesome.
Well articulated presentation, open to all questions, precise with a solid game plan to gain traction in the share price and move our assets into commercialisation.
The underlying factor underpinning our assets is the hugh potential for a T/O or Acquisition. Placing IHL amoungst its peers with market Caps at multipules of where IHL is and with far less assets, market access and portfolio diversification.
I had a good 1hr+ chat with Joel and his dedication drive and passion for IHL and their shareholders is increadable. Yes we will have some pain in the SP during this redomicile period but come November its all systems go. The critisism about Joel on HC is totally unfounded and one needs to look at fundamentals, what the company is doing and acheiving behind the scenes and the wealth of expertise the team have all experts in their feild and second to non. IHL are truely world class and ahead of their compeditors.
GLAH
---------------------------------------------------------------------------------------------------------------
Thanks so much, @von for;IHL Shareholders meeting Melbourne 24 August 23
Masses of information and moving parts, shared last night. So apologies if not all correct.
Was keen to get a “feel” for the team, and their ability to successfully manage cross border, time zones, fast pace, and multiple projects.
Joel very pumped, articulate, and driven, but feel there is good balance from Chairman (Troy Valentine) and no doubt other Board Members. Additional resources being added. Head of Corporate Development (USA based), will concentrate on Co-funding, Outsourcing, Joint Development, Acquisition
Three way confirmation of the value of Bob Clark.
- Due the extensive due diligence he conducted before agreeing to join (am sure he would have had many other global offers)
- Has not been on any other Boards (outside his employer)
- Has a significant track record in successful FDA/IND submissions. 35 years in the game and a 15/15 hit rate. He is incentivised to get results
- Good to see focus on key assets, with structured project management teams allocated
- AUD research and development remains, enabling R &D Tax breaks on well resourced and managed projects (and can’t help thinking this would be an attractive piece for partner/acquirer)
- Clarion Clinics has had excellent patient enquiry response, PR campaign about to ramp up in this area, and assumptions about profit margin looking good.
- Top 40 shareholders hold 47% of company.
- For Redomicile on Nasdaq: IXL need to get shareholder vote across the line.
- Alternative (delisting (ASX) without shareholder support) not palatable, but IHL is not staying on ASX - multiple reasons for others to expand on.
- Important for holders to ensure Automic has current email, contact telephone and postal address for information to be sent.
- Work in progress to make transition to NASDAQ as seamless as possible. A full recommendation about USA share registry/broker, tax information from Pitcher Partners and other requirements, will be released shortly in a package.
- Lots building behind the scenes for release post Nasdaq listing
- Among other things first time attending JP MORGAN Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA. (Appears to be a significant showcase opportunity)
-----------------------------------------------------------------------------------
Glah and see some of you from 4pm?Date: 29th August
Time: Commencing at 6:00 PM
Location: Studio 3 , W Hotel Brisbane
Address: W Hotel Brisbane, 81 North Quay, Brisbane, Queensland 4000
https://hotcopper.com.au/threads/ann-ihl-provides-shareholder-information-events-for-redomiciling.7518526/page-65?post_id=69452895
Have a good week
